Ergoloid Mesylates API Powder 

Ergoloid mesylates (also known as dihydroergotoxine mesilate) is a mixture of hydrogenated ergot alkaloids. Specifically, it contains salts of dihydroergocornine, dihydroergocristine, and the α- and β-isomers of dihydro-ergocryptine. These are derived from the ergot fungus, but unlike older ergot drugs, the “dihydro” formulation has no significant vasoconstrictor activity. The API powder (USP grade) is used to produce oral tablets (typically 1 mg strength) for prescription use.

Ergoloid mesylates is prescribed mainly for elderly patients with mild age-related cognitive decline or dementia symptoms. In practice it is used to treat subtle problems in memory, concentration, mood, or alertness in older adults (generally over 60) who do not have a clearly reversible condition. For example, label information notes it can provide “some symptomatic relief” in individuals with idiopathic dementia (such as Alzheimer’s or multi-infarct dementia). The exact mechanism is not fully understood. It is believed to enhance cerebral metabolism and blood flow. (Ergoloid mesylates does not constrict blood vessels like ergotamine; it was once considered a mild cerebral vasodilator or “metabolic enhancer”.)

• Dosage: Treatment is oral only. Typical dosing is 1 mg (tablet) three times daily. The tablet or sublingual form is swallowed or placed under the tongue. Clinical effect is usually gradual – patients may need 3–4 weeks of daily use before any improvement is seen. After initial therapy (often several weeks), dosing may be continued once or twice daily for maintenance. (The API powder is used in compounding these tablets or sublingual troches.) Therapists advise regular use for months, with periodic evaluation, since benefits tend to be modest.

• How it works: Ergoloid mesylates is thought to improve brain function indirectly. It may mildly block peripheral α-adrenergic receptors, causing a slight BP reduction and increased blood flow to the brain. It may also enhance neuronal metabolism. In summary, it “may slightly decrease blood pressure and heart rate” and is believed to increase cerebral perfusion. However, evidence is mixed: some studies have shown small improvements in alertness, memory and confusion, while others show little benefit. It is not a cure; it may only slow decline or stabilize function in some patients.

Side Effects and Adverse Reactions

Ergoloid mesylates is generally well tolerated, but side effects can occur. Most are mild or transient:

• Gastrointestinal: Common complaints include nausea, vomiting, loss of appetite, and abdominal cramps. These often occur when starting therapy.
• Neurological: Headache and dizziness are reported. Some patients note feeling sleepy or restless. Vision changes (blurred or tunnel vision) or nasal congestion may also occur.
• Cardiovascular: Because it can lower vascular tone, orthostatic hypotension (lightheadedness on standing) is relatively common. Episodes of bradycardia (slow heart rate), tachycardia (fast or irregular heartbeat), or palpitations have been observed. Patients should move slowly when rising to minimize dizziness.

Less common but serious side effects (though rare) include: severe hypotension or syncope, arrhythmias (irregular heartbeats), and neurological reactions. The label warns that very stiff muscles with high fever or other neurological signs are possible (these resemble serotonin syndrome). Eye-related reactions (eye pain, worsened glaucoma with blurred vision or “halos” around lights) have been reported. Because ergoloid mesylates can affect the heart’s conduction, any new chest pain, severe palpitations, or fainting should be evaluated promptly.

• Allergic Reactions: Hypersensitivity reactions are rare but can occur, especially in patients with ergot allergies. Signs include rash, itching, swelling of the face or throat, and breathing difficulty. Any such reactions require immediate discontinuation and medical attention.

Side effects often diminish over time or with dose adjustment. Patients should report any persistent or worrisome symptoms (especially severe dizziness or heart palpitations) to their physician.

Precautions and Interactions

Before using ergoloid mesylates, doctors consider the following:

• Contraindications: Ergoloid mesylates should not be used by patients who have shown hypersensitivity to ergot alkaloids or any component of the tablet. The drug is also contraindicated in acute or chronic psychosis. It is not indicated for children or young adults; its use has been studied only in older adults.

• Cardiovascular risk: Although ergoloid mesylates lacks the potent vasoconstriction of older ergots, it can still affect blood pressure and heart rhythm. Use caution in patients with significant cardiovascular disease. Because it can blunt the effect of nitroglycerin, patients on nitrates (e.g. for angina) may have reduced relief from chest pain if also taking ergoloids. Conversely, the combination may increase risk of coronary vasospasm.

• Drug Interactions: Ergoloids are metabolized by the liver enzyme CYP3A4. Strong CYP3A4 inhibitors (such as ketoconazole or itraconazole) significantly raise ergoloid levels, and concurrent use is generally contraindicated. Macrolide antibiotics (e.g. clarithromycin) and protease inhibitors may also increase exposure. Patients should avoid these combinations or be closely monitored. Many other drugs (like serotonin agents, some antipsychotics, or hormone therapies) can interact with ergot alkaloids; always inform your doctor of all medications and supplements.

• Pregnancy and Breastfeeding: This medication is not recommended during pregnancy or nursing. Ergoloid mesylates belong to the ergot class, which can cause uterine or fetal blood vessel constriction in animal studies. Although specific human data are lacking, the drug is generally avoided because of potential fetal harm. Nursing mothers should also not use ergoloids since excretion into breast milk is unknown and ergot alkaloids are contraindicated in lactation.

• Other: Patients should have a full evaluation to exclude reversible causes of dementia (such as vitamin B₁₂ or thyroid deficiency) before starting ergoloids. Kidney or liver impairment usually does not require dose changes, but overall health and mental status should be monitored. Since the benefit is typically small, continued use should be re-assessed periodically by the physician.

Patient Counseling: Patients or caregivers should be told that ergoloid mesylates is long-term therapy taken daily by mouth. Improvement is gradual, and therapy must be continued to maintain any benefit. Advise moving slowly from sitting to standing to reduce dizziness (orthostatic hypotension). Report any severe side effects (like chest pain, marked irregular heartbeat, vision loss, or allergic reactions) immediately. Because of pregnancy risks, women of childbearing potential should avoid becoming pregnant while on this drug. Do not take any new medications (especially erectile dysfunction drugs, migraine medications containing ergotamine, or antibiotics like ketoconazole) without consulting a physician due to interaction risk.

Summary

• What it is: A mixture of dihydro-ergot alkaloids used as a cognitive enhancer in older adults with mild dementia or senile symptoms.
• How given: Oral tablets, 1 mg three times daily is typical; effects may take weeks to appear.
• Common side effects: Gastrointestinal upset (nausea, abdominal cramps), headache, blurred vision, flushing, and low blood pressure especially on standing.
• Serious risks: Heart rhythm changes or severe hypotension (rare), allergic reactions, and potential neurological or eye complications.
• Precautions: Not for use in pregnancy, nursing, or psychosis. Use cautiously with heart disease or low-pressure states. Avoid interacting drugs (strong azoles, certain antibiotics, nitrates).
• Monitoring: Regular doctor visits to assess benefits and side effects; lab tests are not usually needed but neurological and blood pressure monitoring is important.

Ergoloid mesylates is a prescription substance and should only be used under a doctor’s guidance. Always follow the prescribing information and report any new health concerns during treatment.